Table 1.
Baseline of training set and validation set
| Variables | Training set (n = 77) | Validation set (n = 31) | P |
|---|---|---|---|
| Age | 52.12 ± 9.97 | 51.03 ± 9.70 | 0.607 |
| Menstruation | |||
| Premenopause | 34 (44%) | 16 (52%) | 0.572 |
| Menopause | 43 (56%) | 15 (48%) | |
| T stage | |||
| II | 15 (19%) | 3 (10%) | 0.458 |
| III | 41 (53%) | 18 (58%) | |
| IV | 21 (27%) | 10 (32%) | |
| N stage | |||
| 0 | 11 (14%) | 2 (6%) | 0.322 |
| I | 54 (70%) | 20 (65%) | |
| II | 3 (4%) | 3 (10%) | |
| III | 9 (12%) | 6 (19%) | |
| BMI | 23.96 ± 3.40 | 22.64 ± 2.49 | 0.052 |
| ER | |||
| ≥10% | 40 (52%) | 15 (48%) | 0.738 |
| < 10% | 37 (48%) | 16 (52%) | |
| PR | |||
| ≥10% | 39 (51%) | 20 (65%) | 0.238 |
| < 10% | 36 (47%) | 11 (35%) | |
| HER2 | |||
| Positive | 34 (44%) | 11 (35%) | 0.408 |
| Negative | 43 (56%) | 20 (65%) | |
| Ki67 (%) | 43.64 ± 20.69 | 39.84 ± 19.39 | 0.382 |
| GNRHa | |||
| Yes | 20 (26%) | 9 (29%) | 0.812 |
| No | 57 (74%) | 22 (71%) | |
| CARMN expression | |||
| High | 61 (79%) | 21 (68%) | 0.207 |
| Low | 16 (21%) | 10 (32%) | |
| NAC Response | |||
| Complete response | 47 (61%) | 15 (48%) | 0.284 |
| Partial response | 30 (39%) | 16 (52%) | |
BMI body mass index, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, GNRHa Gonadotropin-releasing hormone analogue, NAC neoadjuvant chemotherapy